Alumis Q1 Results Highlight Strong Psoriasis Data Amid Ongoing Cash Burn

What happened

Alumis reported Q1 2026 financials with continued heavy losses and highlighted a late-breaking oral presentation of Phase 3 envudeucitinib data at AAD showing robust skin clearance and symptom improvement. While the data reinforce envudeucitinib's competitive profile, the company remains pre-revenue with a cash burn of ~$110M per quarter and no near-term path to profitability. The stock has already rallied significantly on prior Phase 3 results, and the new presentation does not materially alter the competitive landscape vs. once-daily rivals like Takeda's zasocitinib. Management emphasized progress toward a 2H26 NDA filing, but the $2.5B market cap already discounts approval and optimistic market share. With no revenue and continued dilution risk, the risk/reward remains unfavorable at current levels despite the positive clinical news.

Implication

Investors should view the AAD presentation as a non-event for the stock's fundamental thesis. The clinical data were widely anticipated and already priced in. The real risks remain: (1) envudeucitinib's twice-daily dosing vs. once-daily competitors; (2) a cash burn that could require additional dilution before profitability; (3) lupus data in Q3 2026 which is a high-risk binary event. We see better risk/reward at entry below $17, or after lupus results de-risk the broader pipeline. Maintain trim/reduce stance.

Thesis delta

The new positive data do not alter our thesis. We continue to view Alumis as overvalued relative to its fundamental prospects. The robust efficacy shown at AAD was largely expected, and the key differentiators — safety, dosing convenience, and lupus data — remain unresolved. No change to our POTENTIAL SELL rating.